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Highlights
• The immediate postoperative period after open heart surgeries with extracorporeal circulation 
is accompanied by immunosupression developing independently of the presence or absences of 
postoperative complications. 
• Elevated levels of monocytic myeloid-derived suppressor cells and IL-10, an anti-inflammatory 
cytokine, are associated with a complicated postoperative period and persistence of multiple organ 
dysfunction syndrome.
E.V. Grigoryev1,2, D.L. Shukevich1,2, V.G. Matveeva1, R.A. Kornelyuk1,2 
Aim To define the role of myeloid-derived suppressor cells in the development of persistent multiple organ dysfunction followed cardiac surgeries with cardiopulmonary bypass.
Methods
40 patients who have undergone cardiac surgery were included in the study. 
Granulocyte myeloid-derived suppressor cells (G-MDSC) were defined as cells 
with the HLA-DR– / CD11β+ / CD15+ / CD33+ phenotype, and monocytic MDSC 
(M-MDSC) as cells with the HLA-DR– / CD11β+ / CD14+ / CD33+ phenotype 
using flow cytometry. Levels of cytokines, IL-1β, IL-6, TNF-α, and IL-10 were 
measured with an enzyme immunoassay. All patients were assigned to three 
groups: Group 1 – patients with the uncomplicated postoperative period (n = 14), 
Group 2 – patients with non-persistent MODS and its early resolution (n = 16), and 
Group 3 – patients with persistent MODS at day 7. 
Results
We observed an increase in M-MDSCs and G-MDSC at day 1 following cardiac 
surgery. The most pronounced increase was found in monocytic-myeloid derived 
suppressor cells, i.e. an 8-fold increase in M-MDSCs in all study groups at day 1 
after surgery. The number of M-MDSCs remained high in patients with persistent 
MODS at day 7 after cardiac surgery. Levels of IL-6 and IL-10 increased at day 1 
after surgery. IL-6 reached its peak level, significantly exceeding baseline levels. 
By day 7, blood levels of all cytokines have decreased, except IL-10 levels, which 
remained above the baseline in patients with persistent MODS.
Conclusion
An increase in M-MDSCs and elevated serum levels of the anti-inflammatory 
cytokine IL-10 have been found in patients regardless of the presence or absence 
of the complications in the early postoperative period after cardiac surgery with 
cardiopulmonary bypass. Persistent MODS with the SOFA scoring > 5 scores 
at day 7 after cardiac surgery, is associated with an increase in M-MDSCs and 
elevated levels of the anti-inflammatory cytokine IL-10, related to higher rate of 
hospital infections, prolonged intensive care unit stay and higher mortality.
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Background
According to the WHO, of the 56.4 million deaths 
worldwide in 2015, more than half (54%) were due to 
cardiovascular diseases (CVD) (coronary artery disease 
and stroke) [1]. These diseases remain the leading 
causes of deaths in the last 15 years. Treatment for 
coronary artery disease depends on severity. In selected 
patients, surgery or other procedures might be needed 
(isolated coronary artery bypass graft (CABG) or 
combined with endovascular procedures or heart valve 
repair). However, a target of 300 CABG procedures per 
million adult population was set in Russia. But, mainly 
regions with direct access to cardiac surgery conform to 
200 CABG operations [2]. Despite all recent advances 
in optimizing myocardial protection, cardiopulmonary 
bypass, and the use of minimally invasive approaches, 
heart surgeries still require extracorporeal circulation, 
myocardial protection from injury during aortic cross-
clamping and cardioplegic cardiac arrest by injecting 
cardioplegic solutions in the coronary bed. It leads 
to myocardial ischemia-reperfusion injury which 
remains the primary cause of acute heart failure 
during the restoration of spontaneous circulation and 
results in the onset of post-perfusion multiple organ 
dysfunction syndrome (MODS) [3–6]. The presence of 
comorbidities may also complicate the course of the 
postoperative period in patients with CVD following 
surgical repair. One theory is that comorbidities are 
associated with chronic organ dysfunctions, which 
significantly worsens the process of patient recovery 
and counteract the regression of MODS [7–11].
Systemic inflammation and, as a consequence, the 
genetic determination of the so-called host response, 
can regress even in the presence of the significant 
clinical risk factors (shock, prolonged ischemia and 
reperfusion, comorbidities) [12, 13]. The systemic 
inflammatory response syndrome (SIRS) in the 
pathogenesis of sepsis has been studied well, whereas 
sterile inflammation (a pathological condition caused 
by ischemia-reperfusion injury during on-pump 
surgeries, severe combined trauma, cardiogenic shock) 
remains a source of discussion. One of the most 
significant mechanism, requiring particular attention, 
is the relationship between the host response and sterile 
factors initiating the SIRS [14–17].
Immunosuppression is actively involved in the 
development of multiple organ dysfunction in critically 
ill patients with prolonged ICI stay. There is a fairly 
extensive evidence-based experimental and clinical 
data suggesting immunosuppression to play a key role 
in the genesis of long-term MI [18–20].
The recent experimental and clinical trials focused 
on the growth and development of tumors determined 
a new population of immature myeloid cells with 
immunosuppressive properties, which were called 
myeloid-derived suppressor cells (MDSC) [21, 22]. 
Most of the clinical trials studied the role of MDSC 
in the development of tumors, reporting the presence 
of immune suppressive effects of this cell population 
[23]. However, recent studies demonstrated that the 
role of MDSC is not limited to cancer patients, but 
might have beneficial effects on any chronic or acute 
inflammation [24, 25].
Extracorporeal circulation is an ideal model of 
the systemic inflammatory response due to non-
physiological activation of tissue factors during 
extracorporeal perfusion, the use of non-pulsatile flow 
during CPB, intentional / unintentional hypothermia, 
bacterial translocation from the gut following 
perfusion deficit and activation of danger-associated 
molecular patterns (DAMPs) [26, 27]. Monocyte cells 
during uncomplicated CPB show their suppressor 
function, which may be a predictor of CPB-associated 
complications.
Therefore, the aim of our study was to determine 
the role of myeloid supressor cells in the development 
of persistent multiple organ dysfunction syndrome 
following cardiac surgery with CPB. 
Methods
Study population
An observational prospective study was initiated 
as a part of the project “Myeloid-Derived Suppressor 
Cells in Cardiac Surgery Patients (MyDeCCS, NCT 
02902939). 40 patients admitted to the ICU after 
elective cardiac surgery with CPB from September 
2016 to March 2017 were included in the study (Table 
1). All the patients were older than 18 years old. We 
excluded from the study patients with estimated life 
expectancy of fewer than 48 hours, those who were 
transferred to the ICU on corticosteroids and other 
hormonal drugs, and those who received permanent 
immunosuppressive therapy and were treated for acute 
coronary syndrome. Patients did not sign informed 
consents because the study was observational.
All the patients were divided into three groups: 
Group 1 – patients with the uncomplicated postoperative 
course (n = 14), Group 2 – patients who had non-
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persistent MODS with symptom resolution in the 
postoperative period (n = 16), and Group 3 – patients 
with persistent MODS without symptom resolution 
(n = 10). Group assignment principle was used as in 
[14]. Group 2 patients with MODS, which resolved 
at day 7, demonstrated a decrease in the SOFA scores 
(<5 scores), whereas Group 3 patients with persistent 
MODS had > 5 SOFA scores.
Standard treatment protocol
All patients underwent cardiac surgery (coronary 
artery bypass grafting or heart valve repair or combined 
surgeries; details of the performed cardiac procedures 
are presented in Table) with CPB using the heart-lung 
machines (Terumo System1, Jostra HL20, Japan) 
and oxygenators (Eurosets, Italy). Extracorporeal 
circulation was performed using non-pulsatile 
(normothermia – 80% of patients, 20% – superficial 
hypothermia) flow with the calculated perfusion index 
of 2.5–2.7 l/min/m2. Cold blood cardioplegia was used 
in 78% of patients according to the standard perfusion 
protocol. Custodiol cardioplegic solution (Dr. F. 
Kohler Chemie, GmbH, Germany) was used in patients 
undergoing heart valve repair. The optimal method of 
cardioplegia delivery was confirmed together with the 
surgeon. Local standard hemodynamic and laboratory 
monitoring, including Swan-Ganz catheter, calculation 
of oxygen delivery and consumption, and blood gas 
analysis, was performed.
Anesthesia: endotracheal anesthesia, induction, 
and maintenance – total i.v. anesthesia with propofol 
at dose rate of 0.1–0.3 mg/kg/min (Propofol Lipuro, 
BBBrown, Germany) and fentanyl at dose rate of 1–3 
μg/kg/h, myoplegia with atracurium (“Tracrium”, 
Wellcome Foundation, Ltd., Great Britain) at dose rate 
of 0.3–0.6 mg/kg/h. The adequacy of anesthesia was 
assessed according to the level of BIS.
Phenotype analysis
Peripheral venous blood was collected into a 
sterile K3-EDTA VACUTAINER blood collection 
tube before the surgery (point 0), at day 1 (point 1), 
at day 2 (point 2) and at day 7 (point 3) after cardiac 
surgery. Cytofluorimetric analysis was performed 
using a four-channel flow cytometer FACS Calibur 
(Becton Dickinson, USA). All samples were prepared 
according to the manufacturer’s protocol. HLA-DR 
monoclonal antibodies conjugated to FITC (BC), 
CD11β-PE, CD15-PerCP, CD14-PerCP and CD33-
APC (BioLegend, USA) were used. 100 μl of whole 
blood with monoclonal antibodies were incubated 
for 30 minutes in the dark at room temperature. Red 
blood cells were lysed using diluted BD lysing solution 
(Becton Dickinson, USA). Then, all the samples were
Table. Baseline characteristics of the study population in the preoperative period, Me (min-max)
Note: * – N/A – not applicable; p<0.05 when comparing Groups 1 and 2, ** – р<0.05 when comparing при Groups 1 и 3, # – р<0.05 
when comparing Groups 2 and 3.
Parameter
Patients with the 
uncomplicated 
postoperative course
(Group 1, n = 14)
Patients with MODS 
regression
(Group 2, n = 16)
Patients with 
persistent MODS
(Group 3, n = 10)
Age, years 57.2 (42.0–66.0) 59.2 (48.0–66.9) 67.2 (49.0–77.0)
Male, % 14 (100) 15.0 (93.75) 8 (80)
Body mass index, kg/m2 33.4 (32.1–35.2) 36.4 (32.0–36.7) 31.4 (31.1–33.2)
Comorbidity index, CIRS, scores 9.6 (8.0–11.1) 9.0 (8.9–11.5) 10.8 (9.9–12.1)
CABG, % 8 (57) 8 (50) 5 (50)
Heart valve repair % 2 (14) 4 (25) 3 (30)
Combined surgeries, % 4 (29) 4 (25) 2 (20)
MODS causes:
– low cardiac output syndrome
– acute massive blood loss
– combination 
N/A
8 (50)
8 (50)
0
4 (40)
3 (30)
3 (30)
Renal replacement therapy sessions per patient 0 0.5 (0–1.2) 2.3 (2.1–4.3)** / #
Initial APACHE II scoring, scores 1.2 (1.0–3.4) 10.9 (9.7–13.5)* 26.6 (19.0–28.9)** / #
Initial SOFA scoring at admission to the ICU, 
scores 0.9 (0–1.9) 5.6 (5.1–7.8)* 7.8 (7.1-12.0)**
ICU stay, days 3 (1–4) 11 (10–14)* 21 (19-33)* / ** / #
Postoperative infections, % 0 10 (62.5) 10 (100)
28-day mortality, % 0 9 18
washed in phosphate buffered saline (PBS) of high 
concentration. The HLA-DR / CD11β / CD15 / CD33 
panel was used to detect G-MDSC, and the HLA-DR / 
CD14 / CD33 panel – M-MDSC. Flow cytometer 
parameters were the same for all samples. M-MDSC 
population was gated on an SS / CD14 bivariate 
histogram, and G-MDSC population – on an SS / CD15 
plot. G-MDSC were defined as cells with the HLA-DR– 
/ CD11β+ / CD15+ / CD33+ phenotype, and M-MDSC 
as cells with the HLA-DR– / CD11β+ / CD14+ / CD33+ 
phenotype.
Level of cytokines, IL-1β, IL-6, TNF-α and IL-
10, were measured by an enzyme immunoassay using 
the manufacturer’s protocol (Bender Medsystems, 
Germany).
The total peripheral white blood cells count was 
computed in the standardized clinical diagnostic 
laboratory of the Research Institute.
Statistical analysis
The mean and median were calculated using a 
GraphPad Prism Software Version 6 (GraphPad 
Software, Inc., USA). The Kruskal-Wallis test and the 
t-test with the Bonferroni-Dunn correction were used 
for multiple comparisons.
Results 
According to the baseline data (Table 1), patients 
with persistent MODS and non-persistent MODS, 
resolved within several days, had similar age, gender 
and the number of comorbidities. However, patients, 
included in Groups 2 and 3, had significantly higher 
APACHE II scores, compared to Group 1 patients. The 
between-group comparison reported that combined 
surgeries prevailed in Groups 2 and 3, compared 
to Group 1 patients. However, this difference did 
not quite reach statistical significance. Low cardiac 
output syndrome was the most common cause of the 
postoperative MODS onset. Group 3 patients with 
persistent MODS had significantly higher SOFA 
scores and the number of renal replacement therapy 
sessions, performed according to the presence of renal 
and non-renal indications. Groups 2 and 3 patients had 
significantly prolonged ICU stay, compared to Group 1 
patients. Group 3 patients had significantly higher rate 
of infections of various locations, compared to Group 
2 patients with non-persistent MODS. No cases of 
infections detected in Group 1 patients.
Serial changes in the number of MDSCs are 
presented in Figures 1 and 2 (G- and M-MDSC, 
respectively).
At day 1 after cardiac surgery with cardiopulmonary 
bypass, the number of M- and G-MDSCs increased in 
all study groups. The following trend in G-MDSCs has 
been found: the increase in their number was detected 
after the surgery, but the between-group comparison 
did not report any statistical difference. It should be 
noted that the portion of G-MDSCs was higher in 
patients with persistent MODS at day 3, compared to 
the other study groups. However, the data scattering 
did not allow us confirming the reliability of the above-
described differences.
The most pronounced increase was observed for 
monocytic-myeloid derived suppressor cells, i.e. an 
8-fold increase in M-MDSC at day 1 after the surgery (the 
differences are significant in comparison with the baseline
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Figure 1. Serial changes in the number of G-MDSC in the 
study groups
Note: Group 1 – patients with the uncomplicated postoperative 
course. Group 2 – patients with MODS and its regression at 
day 7 (the SOFA scoring < 5 scores). Group 3 – patients with 
persistent MODS at day 5 (the SOFA scoring > 5 scores). 
Points: 1 – baseline values, 2 – day 1, 3 – day 2, 4 – day 7 (for 
all plots). The Y-axis – G-MDSC, %.
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levels, but they did not reach statistical significance in 
the between-group comparison). At day 7, the number 
of M-MDSCs decreased to baseline in patients without 
MODS. The percentage of M-MDSCs increased in 
Groups 2 and 3 at day 7 after surgery. The highest level 
of M-MDSCs was observed in patients with persistent 
MODS.
At day 1 after cardiac surgery, all cytokine levels 
increased (Figure 2). The most significant changes 
were found in the levels of TNF-α, IL-6 and IL-10. 
The level of TNF-α was significantly higher at day 
2 postoperatively, compared to that level at day 1 in 
Groups 1 and 2. At day 7, it decreased to the values, 
which are comparable with the comparison groups. 
IL-6 achieved its peak level at day 2 after cardiac 
surgery, compared to that at day 1. At day 7, blood 
levels of cytokines decreased.
Elevated levels of IL-10 were observed in patients 
with the complicated postoperative course and those 
with persistent MODS, compared to baseline levels 
and according to the between-group analysis. 
Discussion
According to the obtained results, we concluded 
that the use of standard clinical and laboratory criteria 
for systemic inflammatory response in cardiac surgery 
may be misleading, if diagnostic criteria of the SIRS 
are extrapolated from the R. Bone's sepsis classification 
without considering the sensitivity and specificity of 
the latter with respect to CPB, cardioplegic arrest and 
peculiarities of cardiac surgeries (i.e. hypothermia, non-
pulsatile flow, hemostatic derangement, etc.) [28, 29]. 
Along with other researchers, we have demonstrated 
the need to improve laboratory instruments for the SIRS 
criteria, particularly with regard to the possibility of 
introducing parameters for assessing innate immunity [30].
The results obtained in the previous studies 
demonstrate that blood levels of all cytokines (IL-1β, 
IL-6, IL-10, and TNF-α), particularly IL-6 and IL-10, 
increase significantly at day 1 following cardiac surgery 
with CPB. The early postoperative period in cardiac 
patients undergoing surgery with CPB is commonly 
characterized by the onset of SIRS of varying severity, 
accompanied by hypercytokinemia [31, 32].
Currently, it is quite clear that in critically ill 
patients, who have trauma, sepsis, etc., inflammation 
and immune suppression occur almost simultaneously 
for a long-term period. Mortality rate in critical patients 
with MODS decreased to 23–25%, but remains at this 
level due to the effects of persistent inflammation, 
which is known as catabolic MODS. Moore et al. 
[20] introduced the term persistent inflammation, 
immunosuppression, and catabolism syndrome (PICS) 
to cover this critical state.
One of the hypotheses suggests that 
immunosuppression is induced in patients without 
comorbidities and during uncomplicated CPB with 
an average duration of the aortic cross-clamping. This 
concept is confirmed by an increase in the expression 
of anti-inflammatory cytokines and a decrease in HLA-
DR expression [33]. A number of studies have proven 
that immune suppression appears to be a basis for the 
onset of persistent MODS, but the exact underlying 
mechanisms of the latter are still unclear. Clinical, 
laboratory, immunological and genetic markers have
Figure 2. Serial changes in cytokine serum levels in the study 
groups
Note: Group 1 – patients with the uncomplicated postoperative 
course. Group 2 – patients with MODS and its regression at 
day 7 (the SOFA scoring < 5 scores). Group 3 – patients with 
persistent MODS at day 5 (the SOFA scoring > 5 scores). Points: 
day 1, day 2, day 7 (for all plots).
89E.V. Grigoryev et al.
already been identified, but monitoring parameters 
require further clarification [34].
Extreme myelopoiesis has been reported to result 
in the expansion of myeloid-derived suppressor cells 
to the bone marrow, secondary lymphoid organs with 
the reticuloendothelial system [35]. Myeloid-derived 
suppressor cells are a heterogeneous cell population 
and may potently suppress T cell functions due to the 
production of iNOS, arginase and reactive oxygen 
intermediate (ROI) [36]. The activity of such cells 
directly correlates with immune suppression [37–39]. 
This role is significant and may be a key one in the 
development of persistent inflammation. These cells 
produce a large number of cytokines (IL-10, TNF-α, 
etc) in addition to ROI and nitric oxide, which have 
immunosuppressive effects [40].
IL-10 is of primary importance among other anti-
inflammatory cytokines. Il-10 reaches its peak blood 
concentration within 2 hours after the SIRS onset in 
patients who have undergone cardiac surgery with CPB. 
It starts decreasing at day 2 [41, 42]. IL-10 inhibits 
the production of pro-inflammatory cytokines such 
as IL-6 and TNF-α by macrophages and monocytes, 
reduces the expression of major histocompatibility 
complex molecules, and bone stimulatory growth 
factors, etc. Recent studies have reported the presence 
of the relationship between blood levels of IL-6, 
IL-10 and the risk of infection in the postoperative 
period, which is associated with the development 
of an immunosuppressive phenotype after CPB. We 
noted that anti-inflammatory response in the late 
postoperative period prevailed in cardiac patients 
included in our study due to high levels of IL-10.
MDSCs, obtained from tumor-bearing experimental 
animals and / or cancer patients, are known to produce 
an increased amount of the anti-inflammatory and 
immunosuppressive cytokine IL-10. Therefore, we may 
assume that MDSCs may potentiate IL-10-dependent 
immune suppression and polarization of T-helpers, 
as well as stimulate the formation of regulatory T 
cells [43]. We obtained similar data in our study. The 
expression of M-MDSC increased at day 1 following 
cardiac surgery with CPB, accompanied by elevated 
serum levels of IL-10. However, elevated levels of pro-
inflammatory IL-6 are also of paramount importance, 
as they confirm the presence of the balanced systemic 
inflammatory response to CPB [26].
The role of MDSCs in the development of sterile 
systemic inflammatory response requires further 
investigation. Currently, there is lack of studies as we 
found only one study focused on the involvement of 
M-MDSCs in the development of infectious pulmonary 
complications following surgeries with CPB [33, 44].
We confirmed in a relatively small cohort of 
patients that prolonged MODS with the SOFA scoring 
> 5 scores is associated with higher proportion of 
cells with the HLA-DR– / CD11β+ / CD14+ / CD33+ 
phenotype and elevated levels of anti-inflammatory 
cytokine, IL-10, related to immune suppression. During 
the inflammation, the release of MDSC and analogues 
increases dramatically due to both DAMPs and PAMPs 
(pathogen-associated molecular patterns) activity, 
leading to the extreme reorganization of myelopoiesis. 
Myeloid cells play important role in the realization 
of the innate immune response, in the release of 
systemic inflammatory mediators and in the activation 
of the acquired immune response [45]. Normally, 
the physiological quantity of mature neutrophils and 
monocytes is achieved due to uniform myelopoiesis. In 
acute inflammation, mature neutrophils and less mature 
cells mobilized from blood and bone marrow are guided 
to the exact location of the inflammatory focus with 
underlying systemic endotheliosis and SIRS-induced 
vasculitis [31]. The result of this response is the rapid 
depletion of bone marrow reserves and the ejection of 
local mediators, causing “urgent” myelopoiesis.
Conclusion
An increase in M-MDSCs and elevated serum 
levels of the anti-inflammatory cytokine IL-10 have 
been found in patients regardless of the presence or 
absence of the complications in the early postoperative 
period after cardiac surgery with cardiopulmonary 
bypass. Persistent MODS with the SOFA scoring > 
5 scores at day 7 after cardiac surgery, is associated 
with an increase in M-MDSCs and elevated levels of 
the anti-inflammatory cytokine IL-10, related to higher 
rate of hospital infections, prolonged ICU stay and 
higher mortality.
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